Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Evotec SENASDAQ: EVO

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital turns positive

Q1 FY2026 change in working capital was €72.67M, compared with -€33.2M a year earlier. Trailing-twelve-month change in working capital was €44.49M.

Context

  • Change in working capital amounted to 7.7% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly change in working capital holds near €72.67M or moves back toward the trailing-twelve-month quarterly average of €11.12M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€72.67M+1174.5% QoQ
Last fiscal yearDec 2025
-€58.4M-14.4% YoY
LTMMar 2026
€44.49M+205.7% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+318.9%——
1 year-14.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

EUR · from the cash flow

Latest · FY2025
(58.4M) EUR
Year-over-year change
+14.4%

Change in Working Capital vs competitors

How EVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +205.7% is the highest of 11, against a peer median of +32.0%.
  • Change in working capital amounts to 6.0% of revenue for EVO, versus a peer median of 5.0%.
EVO Competitors
Change in Working Capital for EVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALVOAlvotechLTM Mar 2026$164.8M USD-37.8%+34.9%29.5%
TLRYTilray Brands, Inc.LTM Feb 2026$66.68M USD+65.3%-9.5%5.6%
EVOEvotec SELTM Mar 2026€44.49M EUR+205.7%—6.0%
PCRXPacira BioSciences, Inc.LTM Mar 2026$41.38M USD+62.9%+32.5%5.6%
HROWHarrow Health, Inc.LTM Mar 2026$17.67M USD+1.1%—6.6%
SDGRSchrödinger, Inc.LTM Sep 2026$13.47M USD-112.7%—5.0%
TDOCTeladoc Health, Inc.LTM Mar 2026$5.93M USD+123.8%—0.2%
AZTAAzenta, Inc.LTM Sep 2026$4.06M USD+117.8%—0.7%
PHVSPharvaris N.V.LTM Sep 2026€2.93M EUR-56.1%-3.1%—
SYRESpyre Therapeutics, Inc.LTM Sep 2026$2.19M USD-130.6%+2.5%2.4%
NVCRNovoCure LimitedLTM Mar 2026$653K USD+111.0%—0.1%
Peer median (excluding EVO) —+32.0%+2.5%5.0%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Depreciation & Amortization67.61M83.2M92.98M101.62M95.55M
Deferred Income Tax5.07M21.7M3.32M2.1M14.11M
Stock-Based Compensation7.81M9.92M9.63M5.04M0
Change in Working Capital(2.28M)105.29M(9.94M)(68.21M)(58.4M)
Accounts Receivables(48.03M)(53.68M)00(27.6M)
Inventory(11.65M)(4.41M)00(9.18M)
Accounts Payables31.34M24.55M00(7.02M)
Other Working Capital26.06M138.83M(9.94M)(68.21M)(14.61M)
Other Non-Cash Items(171.47M)161.37M24.37M173.75M39.11M
Operating Cash Flow122.24M205.81M36.44M18.22M(9.06M)
Capital Expenditures(118.94M)(181.35M)(216M)(132.24M)(69.68M)
Acquisitions (Net)(21.09M)(83.82M)(20.16M)42.78M213.76M
Purchases of Investments(123.7M)(355.82M)(48.39M)(29.39M)(13.42M)
Sales of Investments27.25M205.17M260.36M35.67M38.87M
Other Investing Activities(7.38M)3.03M8.22M(2.78M)0
Investing Cash Flow(243.86M)(412.8M)(13.29M)(71.19M)159.86M
Debt Repayment14.77M(53.11M)84.6M(152.07M)(6.96M)
Common Stock Issued404.32M355K00(1.27M)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(20.67M)(5.39M)(12.63M)(9.35M)(22.71M)
Financing Cash Flow398.43M(58.15M)71.96M(161.42M)(30.93M)
Effect of Forex Changes(66K)(19.04M)644K9.87M28.46M
Net Change in Cash276.75M(284.17M)95.75M(204.52M)148.32M
Free Cash Flow3.29M24.46M(179.56M)(114.02M)(78.74M)

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.